Abstract 752P
Background
Adding pembrolizumab (P) to standard first-line chemotherapy +/- bevacizumab in cervical cancer significantly improved survival. However, more than half of patients (pts) will present a relapse before 12 months. Virtually all cases of cervical cancer are attributable to HPV infection. Preclinical evidence suggests that histone deacetylase inhibitor vorinostat (V), might be active in both HPV 16 and HPV 18 related infections and might improve immunotherapy efficacy giving the rationale for combining P + V in cervical cancer.
Methods
PEVOsq is an open-label, non-randomized, multi-center, basket phase II trial, evaluating the efficacy of P+V in pts with recurrent and/or metastatic squamous carcinomas. Pts had to be PD1/PD-L1 antagonist-naïve with no restriction in terms of prior lines of treatments. P dose was 200 mg Q3W IV, and V 400 mg QD PO. Sample size was determined using an A’Hern design. Primary endpoint was objective response rate (ORR) according to RECIST 1.1. Secondary endpoints included safety, progression-free survival (PFS), overall survival (OS), and duration of response (DOR).
Results
Among 112 included pts, 25 were included in the cervix cohort. Median age was 52 years [range(r): 31-75]. The median number of prior lines of therapies was 1 [r: 0-3]. Among 23 pts evaluable for activity criteria, ORR was 39.1% [95%CI: 19.7-61.5]. Median PFS was 4.2 months [95%CI: 2.3-8.2] and OS was 10.3 months [95%CI: 5.7-NR]. DOR was 15.2 months [95%CI 1.4-NR]. Grade 3/4 Treatment related AE were frequent (44%). Seventeen pts (68%) had at least one treatment interruption and/or dose reduction due to toxicity for V including hematotoxicity, gastrointestinal disorders, asthenia, and creatinine increase. Six pts (24%) had at least one administration delayed due to toxicity for P. Median dose intensity for V was 271.4 mg/j [r: 108.7 – 400]. Dose intensity for V was 271.1mg/d [r: 108.7-400.0] and 260.5mg/d [r: 199.4-400.0] in pts with ORR and others (SD/PD), respectively. Results according to PDL1, MSI, TMB and HPV will be presented at the meeting.
Conclusions
Combining P and V in cervical cancer was effective even though dose adaptations for V were frequent.
Clinical trial identification
NCT04357873, EudraCT 2019-003839-33.
Editorial acknowledgement
Legal entity responsible for the study
Unicancer.
Funding
ERAPerMED ANR Fondation ARC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
648P - Medium to long-term effects of the COVID-19 pandemic on colorectal cancer diagnosis and management in Italy: Preliminary findings from an updated analysis of the real-world multicenter COVID-DELAY study
Presenter: Alessandro Parisi
Session: Poster session 11
649P - The genomic landscape of appendiceal adenocarcinoma (AA) revealed by 855 whole exome sequences (WES)
Presenter: Michael White
Session: Poster session 11
650P - Genomic profiling of small bowel adenocarcinoma: A pooled analysis
Presenter: Thomas Aparicio
Session: Poster session 11
651P - DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study
Presenter: Christophe Borg
Session: Poster session 11
726P - Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma
Presenter: Cristina Ronchi
Session: Poster session 11
727P - Clinical outcome of anlotinib (A) and tislelizumab (T) in metastatic adrenocortical carcinoma(mACC): A one-arm single-center experience
Presenter: HAO LI
Session: Poster session 11
728P - Brain metastases in advanced thyroid carcinoma: Clinical and molecular characteristics and outcomes
Presenter: Thais Megid
Session: Poster session 11
729P - Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs): A survival analysis from a prospective observational study
Presenter: Valentina Andreasi
Session: Poster session 11
730P - The outcome of combine radioligand and CAPTEM therapy in patients with advanced, unresectable, progressive GEP-NET
Presenter: Jaroslaw Cwikla
Session: Poster session 11